Biography
Physician, epidemiologist, biomedical engineer, scientist, and entrepreneur, dedicated to optimizing healthcare by translating clinical needs into technical solutions. Previously, led the clinical cardiovascular imaging research group at Stanford Radiology.His clinical and research background allows to identify and address medical shortcomings effectively. Beyond his technical expertise, he has leadership with various international scientific organizations and co-directs educational courses. With over 100 peer-reviewed papers published, 30 international lectures presented, and funding received from prestigious entities, he holds the title of Fellow of the Society of Cardiovascular Computed Tomography (SCCT). His work, acknowledged through numerous awards, reflects significant contributions to the fields of radiology and cardiovascular imaging.

AI and Data Sciences Showcase:
Segmed
Segmed aims to transform healthcare research by extracting valuable information from medical imaging studies for innovative applications. Our platform facilitates global cohort identification, secure extraction, de-identification, and transfer of targeted studies. Linking images to clinical data support research, AI-imaging, disease diagnosis, and treatment.

Biography
In 2019, Dr. Miga co-founded the Telomere-to-Telomere (T2T) Consortium, an open, community-based effort to generate the first complete assembly of a human genome. Additionally, Dr. Miga is the Director of the Reference Production Center for the Human Pangenome Reference Consortium (HPRC). Central to Dr. Miga’s research program is the emphasis on satellite DNA biology and the use of long-read and new genome technologies to construct high-quality genetics and epigenetic maps of human peri/centromeric regions.

Biography
Peter Goodhand is a senior executive and board member in the global health sector. He has been the senior executive of GA4GH since its founding in 2013. Prior to GA4GH, he was the President and Chief Executive Officer of the Canadian CancerSociety and has also served as the President of the Ontario Institute for Cancer Research. Before joining the notforprofit sector, Goodhand had a 20 year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies; Board Chair and President of Canada's Medical Device Industry association (MEDTECH); and as the founding Managing Director and the Board Chair of the Health Technology Exchange(HTX).Goodhand is currently CoChair on the boards of Global Genes and the Global Genomic Medicine Collaborative (GGMC); CoChair of the International 100K+ Cohorts Consortium (IHCC); and a member of numerous international advisory boards.

Biography
Dr. Awadallas main research interests include identifying genomic determinants of blood disorders and cancers, understanding mutation and recombination biology and genomic epidemiology of age-related disorders in population cohorts. Dr. Awadalla leads Canadas largest longitudinal population cohorts to develop precision medicine research and understand the genetic and environmental contributors to disease development. His major projects include genomics of aging, hematological diseases and cancers. Other projects include the genetic and environmental control points for healthy aging, and the development of machine learning approaches to integrate multiple genomic and phenotypic data to predict health outcomes. He is the National Scientific Director of Canadian Partnership for Tomorrows Health, is Director of Computational Biology and the Executive Scientific Director of Ontario Health Study at the Ontario Institute for Cancer Research and is a Professor of in the Molecular Genetics Department and Dalla Lana School of Public Health at the University of Toronto.

Biography
Jensen Huang founded NVIDIA in 1993 and has served since its inception as president, chief executive officer, and a member of the board of directors. Huang has been elected to the National Academy of Engineering and is a recipient of the Semiconductor Industry Association’s highest honor, the Robert N. Noyce Award; the IEEE Founder’s Medal; the Dr. Morris Chang Exemplary Leadership Award; and honorary doctorate degrees from Taiwan’s National Chiao Tung University, National Taiwan University, and Oregon State University. He has been named the world’s best CEO by Fortune, the Economist, and Brand Finance, as well as one of TIME magazine’s 100 most influential people. Prior to founding NVIDIA, Huang worked at LSI Logic and Advanced Micro Devices. He holds a BSEE degree from Oregon State University and an MSEE degree from Stanford University.

Biography
Dr. Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely used tools for analyzing cancer genomes. Dr. Getz is a Professor of Pathology at Harvard Medical School. He is the Director of Bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology, and is an Institute Member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. He has published over 400 papers in prominent journals describing new methodologies to study cancer genomes that have identified new genes and pathways involved in different tumor types, mutational signatures, and tumor evolution.

Biography
Ken Drazan, MD, is the Chairman, CEO, and Co-Founder of ArsenalBio, a pioneering company in the field of cell therapy and gene editing. Prior to his role at ArsenalBio, Dr. Drazan served as President and Chief Business Officer of GRAIL, a company focused on early cancer detection which was acquired by Illumina. He also founded and was a Board Director at Verb Surgical, which was later acquired by Johnson Johnson. Additionally, Dr. Drazan co-founded Bertram Capital, a private equity firm managing $1.9 billion in assets. He earned his medical degree from Yale University. Throughout his career, Dr. Drazan has been instrumental in advancing technologies that leverage AI and high-performance computing in precision medicine, significantly impacting the fields of gene editing and cell therapy.

Biography
Matthias Troyer is working on the system architecture of quantum computers and their applications at Microsoft. Matthias is a Fellow of the American Physical Society and President of the Aspen Center for Physics. He is recipient of the Rahman Prize for Computational Physics of the American Physical Society for pioneering numerical work in many seemingly intractable areas of quantum many body physics and for providing efficient sophisticated computer codes to the community and of the Hamburg Prize for Theoretical Physics.

Talk
I will explore intersection of quantum computing and AI, and their potential to accelerate scientific discovery. Combining the accuracy of quantum computing with the acceleration offered by AI has the potential to transform chemistry, materials science and biology

Biography
Janusz Dutkowski is Founder and CEO of Data4Cure, Inc. a company focused on combining systems biology, machine learning and AI to facilitate continuous translation of biomedical data to knowledge. His background is in mathematics and computer science and he has been working at the intersection of mathematics, computer science and biology to develop new data driven technologies to advance the discovery of new biomarkers and precision based therapies. His research contributions include the development of methods for multiscale analysis of molecular networks and integrative methods for biomarker discovery from multidimensional data. He has co authored over 20 research papers published in scientific journals including Nature Biotechnology, Science and Cell.

Biography
Dr. Rejto leads the development and integration of cutting-edge technologies in drug discovery. With over two decades of experience, he oversees high-throughput screening, structural biology, and computational drug discovery, focusing on enhancing the efficiency and effectiveness of Pfizer's research and development efforts.Dr. Rejto holds a Ph.D. from the University of California, Berkeley, and completed a postdoctoral fellowship at Harvard University. His leadership has advanced the integration of AI and machine learning in drug discovery, contributing to key therapeutic developments. Dr. Rejto is also an active contributor to the scientific community, with numerous publications and patents.

Biography
Dr. Yasin Şenbabaoğlu (SHEN-buhbuh-o-loo) holds a PhD from University of Michigan Ann Arbor and has extensive experience in the biotechnology industry. Dr. Şenbabaoğlu has previously worked at Genentech, where he served in various roles including Senior Principal Scientist in Multimodality AI and Principal Scientist in Oncology Bioinformatics. His responsibilities at Genentech included target discovery and validation in cancer immunotherapy, translational research in cancer immunology, and the application of machine learning for patient and sample selection. Prior to Genentech, he was a Senior Research Scientist at Memorial Sloan Kettering Cancer Center, where he collaborated on cancer immunology projects and set up bioinformatics pipelines. Dr. Şenbabaoğlu's expertise spans machine learning, spatial AI, statistical modeling, bioinformatics, cancer immunology, tumor microenvironment, and molecular oncology.

Biography
Dr. Alokkumar Jha is an Assistant Professor of Research in Neuroscience at Weill Cornell Medicines Brain and Mind Research Institute, specializing in the application of advanced AI models to genomics and imaging data. His research focuses on leveraging machine learning to understand disease progression mechanisms, particularly in neurodegenerative diseases such as Alzheimer's Disease and heart failure.Dr. Jhas current projects include developing deep learning models to analyze genomics data, identifying key features that predict transitions from normal cognitive function to Alzheimer's. His work has been recognized as an "Abstract of Distinction" for its innovative approach to understanding neurodegeneration. He is also involved in collaborative projects investigating somatic variants in heart failure, using graph learning AI models to integrate genetic and MRI data.With a Ph.D. in Cancer Genetics from the National University of Ireland, Galway, and experience at institutions such as Stanford University and Harvard Medical School, Dr. Jha combines multi-omics data, imaging, and AI technologies to create personalized predictions for disease progression and treatment outcomes.

Biography
Dr. Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely used tools for analyzing cancer genomes. Dr. Getz is a Professor of Pathology at Harvard Medical School. He is the Director of Bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology, and is an Institute Member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. He has published over 400 papers in prominent journals describing new methodologies to study cancer genomes that have identified new genes and pathways involved in different tumor types, mutational signatures, and tumor evolution.

Biography
Jensen Huang founded NVIDIA in 1993 and has served since its inception as president, chief executive officer, and a member of the board of directors. Huang has been elected to the National Academy of Engineering and is a recipient of the Semiconductor Industry Association’s highest honor, the Robert N. Noyce Award; the IEEE Founder’s Medal; the Dr. Morris Chang Exemplary Leadership Award; and honorary doctorate degrees from Taiwan’s National Chiao Tung University, National Taiwan University, and Oregon State University. He has been named the world’s best CEO by Fortune, the Economist, and Brand Finance, as well as one of TIME magazine’s 100 most influential people. Prior to founding NVIDIA, Huang worked at LSI Logic and Advanced Micro Devices. He holds a BSEE degree from Oregon State University and an MSEE degree from Stanford University.

Biography
In her research, Orly Alter develops quantum mechanics-based multi-tensor AIML, which, as she prospectively and retrospectively experimentally validated, is uniquely able to discover accurate, precise, clinically actionable, and mechanistically interpretable predictors from small-cohort and noisy, high-dimensional multi-omic data. Alter is the CSO and a co-founder of Prism AI Therapeutics, Inc., a USTAR associate professor at the Scientific Computing and Imaging Institute and the Huntsman Cancer Institute at the University of Utah, and a scientific advisory board member of the NCI-DOE Cancer Moonshot collaboration on predictive oncology. As a genetics postdoctoral fellow at Stanford University, she invented the concept of the eigengene, in a top ten most cited PNAS paper of the year 2000 and a top 50 most cited PNAS paper of all time. Her Ph.D. thesis in applied physics at Stanford University was published by Wiley, and is recognized as crucial to gravitational wave detection and quantum computing.

Biography
Peter Ellman is the President and CEO of Certis Oncology Solutions, a precision oncology and translational science start-up established in 2016 and located in San Diego, California.A serial entrepreneur, prior to his current role Peter led Paradox Dx, a pharmacogenomics business and Nextec Applications, an advanced materials technology company. He served on the board of StrataGene, a publicly held molecular diagnostics company acquired by Agilent in 2007. He also served as founding sales executive for Thermoscan, the worlds first infra-red ear thermometer acquired by Gillette in 2003 and Interplak, an electronic consumer products company acquired by Bausch and Lomb in 1988.

Talk
Explore how AI-driven digital assistants are reshaping oncology research and drug discovery. Learn how these tools simplify access to vast datasets, streamline complex genetic and molecular data analysis, enhance predictive modeling for drug efficacy and drug repurposing, accelerate the development of personalized cancer treatments, and foster innovation in precision medicine.

Biography
Dr. Nicolo Fusi focuses on machine learning and its application to biological data. He is particularly interested in improving drug discovery through computational methods and advancing the field of precision medicine. His research spans causal inference, computational biology, and AI-driven drug discovery, combining cutting-edge AI techniques with large-scale biomedical datasets to drive innovations in healthcare.Before joining Microsoft, Dr. Fusi earned his PhD in Computer Science from the University of Sheffield and has held various research positions that bridge computer science and biology. He has authored numerous peer-reviewed publications and has been recognized for his contributions to the development of AI methodologies in life sciences. His work is instrumental in leveraging AI to transform how diseases are understood and treated.In addition to his research, Dr. Fusi is passionate about collaborating with academic and industry partners to push the boundaries of AI applications in healthcare.

Biography
Noah Nasser is a healthcare executive with over 30 years of experience in biotechnology, genomics, and molecular diagnostics. He is leading efforts to revolutionize healthcare through innovative data solutions, including the launch of a federated real-world data marketplace that enables secure, scalable collaboration and data sharing between custodians and consumers. Previously, Noah was CEO of Serimmune, where he led the company through multiple funding rounds and launched its immuno-mapping technology. He has held senior leadership roles at Human Longevity, Inc., Counsyl, AltheaDx, Verinata Health, and Quidel Corporation, driving commercialization and business growth. Known for his ability to innovate and scale businesses, Noah is positioned to shape the future of healthcare data. He is also an Executive in Residence at the University of Utahs Center for Technology and Commercialization.

Biography
At Ultima Genomics, our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health.To achieve this, we built a revolutionary new sequencing architecture that scales far beyond conventional technologies, enabling scientists to overcome the tradeoffs they face between the breadth, depth and frequency of sequencing.

Biography
At Verily Dr. Trister leads the companys research, science and population health initiatives, providing expertise across Verilys portfolio as the company furthers its precision health strategy. Previously, Andrew served as the Deputy Director of Digital Health and Artificial Intelligence at The Bill Melinda Gates Foundation where he led the Foundations development and investment in digital health and artificial intelligence to address global health inequities. Prior to that, Andrew was a founding member of Apples Health team, where he led clinical research and machine learning with Apple partners. Andrew holds an MD, a PhD in bioengineering, an MSE and BSE in computer science, and a BA in biological basis of behavior from the University of Pennsylvania. He completed his clinical residency in radiation oncology at the University of Washington, with additional focus areas in medical and bioinformatics.

Biography
At Vevo, Johnny Yu is focused on scaling its single-cell genomics platform, Mosaic, for discovery of novel therapeutics. Recently, Vevo applied Mosaic to generate the world's largest single-cell RNA sequencing atlas of 100M cells named Tahoe-100. Vevo continues to push the limits of single-cell data generation with the aim of becoming the world's first pharmaceutical company built on single-cell technologies. Before co-founding Vevo, Johnny Yu trained at UCSF with Dr. Hani Goodarzi and Dr. Kevan Shokat where he built the foundations for Mosaic which enables pan-cancer in-vivo screening. Previous to that, he worked at the Broad Institute and Biogen Idec.

Talk
Tahoe-100M surpasses all publicly available single-cell data and contains 60,000 drug perturbation experiments across 1200 drug treatments and 50 cancer models. It is the first dataset of its kind and will enable machine learning and AI models to rapidly scale in the genomics space.

Biography
Watson’s current work focuses on AI-driven biomolecular design, creating predictive peptides and receptor-targeting ligands that are engineered to precisely deliver nanoparticles, gene-editing tools, drugs, and nucleic acids to specific cells and tissues. This approach aims to enhance therapeutic specificity, reduce toxicity, and accelerate the development of curative and preventative delivery of therapeutics. Previously, while researching at Rensselaer Polytechnic Institute, he developed gene-editing delivery platforms for guided nucleases like CRISPR and TALEN. Today, he applies AI and predictive physics to rapidly generate and evaluate novel targeting agents, mapping uncharted receptor-ligand relationships as an enabling technology for biopharmaceutical delivery systems. With over 80 pending global patents (22 approved, 6 allowed), Watson’s work pioneered integrating cell surface transcriptomics, predictive targeting ligand design, and drug and gene delivery systems. He and his team aim to transform how we approach the world’s most challenging diseases, advancing the frontier of precision therapeutics and diagnostically-responsive medicine.

Talk
Gene therapy, drug delivery, and nanomedicine have advanced alongside Nobel-winning computational protein prediction breakthroughs. This talk introduces LigandAI, a next-generation diagnostically-responsive platform that utilizes AI-driven peptide design and advanced delivery technologies to enable preventative, personalized, and precision tissue-specific targeting for molecular and genetic engineering.

Biography
Luca is a seasoned entrepreneur and expert in technology and healthcare. He currently serves as the Founder and CEO of InSilicoTrials Technologies, a company pioneering the use of modeling and simulation in healthcare and life sciences. Before founding InSilicoTrials, Emili held the position of CEO at Emaze, a cybersecurity firm specializing in automated security analysis for complex networks.

Biography

Biography
Stacie, a former pharma and biotech leader, recently joined NVIDIA to further enable AI adoption across Healthcare and Life Sciences. She also serves as the Vice Chair of the Alliance for Artificial Intelligence in Healthcare (AAIH). In her 13+ years at GSK, she led RD initiatives and co-founded the ATOM consortium. More recently, she held leadership roles at AI Drug Discovery startups Atomwise, where she was a VP of Partnerships, and BioSymetrics, here she was the Chief Strategy Officer. Stacie holds a B.S. in Chemistry from UC Berkeley and a Ph.D. in Organic Chemistry from UC Irvine.